PRECISELY Targeted Therapies for patients with cancer
With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.
Chemistry at the Core
We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.
Built for Patients
We partner with physician-scientists to identify patient needs and the limitations of existing therapies.
Driven by Purpose
We are passionate about using our expertise to address the needs of patients with cancer.
Christopher Cooper, PhD
Pharmaceutical Development

Christopher Cooper, PhD
Pharmaceutical Development
Shannon Dauksis, PharmD
Program Management

Shannon Dauksis, PharmD
Program Management
Jeffrey Lee
Information Technologies

Jeffrey Lee
Information Technologies
Paula Chubet
Legal

Paula Chubet
Legal
Tuan Minh Nguyen, PhD
Biology

Tuan Minh Nguyen, PhD
Biology
Jesus Garza
Financial Planning &
Analysis
Analysis

Jesus Garza
Financial Planning &
Analysis
Analysis
John Soglia, PhD
Translational Development

John Soglia, PhD
Translational Development
Sowjanya Mangipudi
Clinical Operations

Sowjanya Mangipudi
Clinical Operations
Kristi Byrnes
Quality Assurance

Kristi Byrnes
Quality Assurance
Yuting Sun, PhD
Biology

Yuting Sun, PhD
Biology
Virginia Vetter
Regulatory Affairs

Virginia Vetter
Regulatory Affairs
Shashank Kulkarni, PhD
Medicinal Chemistry

Shashank Kulkarni, PhD
Medicinal Chemistry
Nathan McConarty, JD
Legal

Nathan McConarty, JD
Legal
Tina Kehrig
Clinical Operations

Tina Kehrig
Clinical Operations
Jessie Lin
Corporate Strategy &
Portfolio Management
Portfolio Management

Jessie Lin
Corporate Strategy &
Portfolio Management
Portfolio Management
Jenn Fairbanks
Clinical Operations

Jenn Fairbanks
Clinical Operations
Kristin Andrews, PhD
Computational Chemistry

Kristin Andrews, PhD
Computational Chemistry
Jason Kropp
Pharmaceutical Development

Jason Kropp
Pharmaceutical Development
Joshua Lance, JD
Legal

Joshua Lance, JD
Legal
Joshua Horan, PhD
Chemistry

Joshua Horan, PhD
Chemistry
Ray Kemper, PhD
Toxicology

Ray Kemper, PhD
Toxicology
Baudouin Gerard, PhD
Medicinal Chemistry

Baudouin Gerard, PhD
Medicinal Chemistry
Alex Balcom
Chief Financial Officer

Alex Balcom
Chief Financial Officer
Matthew Campbell
Pharmaceutical Development

Matthew Campbell
Pharmaceutical Development
Fareya Zubair
Regulatory Affairs

Fareya Zubair
Regulatory Affairs
Darlene Noci, ALM
Chief Development Officer

Darlene Noci, ALM
Chief Development Officer
Henry Pelish, PhD
Drug Discovery

Henry Pelish, PhD
Drug Discovery
Anupong
Tangpeerachaikul, PhD
Tangpeerachaikul, PhD
Biology

Anupong
Tangpeerachaikul, PhD
Tangpeerachaikul, PhD
Biology
Scot Mente, PhD
Computational Chemistry

Scot Mente, PhD
Computational Chemistry
Benjamin Lane, PhD
Technical Operations

Benjamin Lane, PhD
Technical Operations
Mikhaila Ruth
Human Resources

Mikhaila Ruth
Human Resources
Stephen McNamara
Finance

Stephen McNamara
Finance
Sibao Chen, PhD
Pharmaceutical
Development
Development

Sibao Chen, PhD
Pharmaceutical
Development
Development
Christian Martin
Translational Development

Christian Martin
Translational Development
Morgan Maiola
Quality Assurance

Morgan Maiola
Quality Assurance
Gosia Riley
Clinical Operations

Gosia Riley
Clinical Operations
Matthew Metivier
Human Resources

Matthew Metivier
Human Resources
Christopher Turner, MD
Chief Medical Officer

Christopher Turner, MD
Chief Medical Officer
Deb Miller, PhD, JD
Chief Legal Officer

Deb Miller, PhD, JD
Chief Legal Officer
Lidya Le
Clinical Operations

Lidya Le
Clinical Operations
Viola Zhu, MD, PhD
Clinical Development

Viola Zhu, MD, PhD
Clinical Development
Maureen Secord
Clinical Supply Chain

Maureen Secord
Clinical Supply Chain
Greg Smith
Regulatory

Greg Smith
Regulatory
José Lizarraga
Formulation Sciences

José Lizarraga
Formulation Sciences
Ruth Adams
Clinical Operations

Ruth Adams
Clinical Operations
Brenda Vienneau, CPA, CMA
Finance

Brenda Vienneau, CPA, CMA
Finance
James Porter, PhD
Chief Executive Officer

James Porter, PhD
Chief Executive Officer
Ashlin Miller
Program Management

Ashlin Miller
Program Management
Kevin Staffin
Quality Assurance

Kevin Staffin
Quality Assurance
Kari Andrews
Clinical Operations

Kari Andrews
Clinical Operations